longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Biogen

BIIB

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 40.07, above the reasonable range, cheaper than 0.13% of the time in the past 3 years, and the industry ranks 50/602, the industry Median -2.32.

40.07xP/E
$226.36Stock price
$5.65Earnings per share
40.07xP/E
Stock price$226.36Earnings per share$5.65

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
21.09x
Typical range
13.27x–27.15x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
VRTXUSVertex Pharma
30.06x36.49%$132.40B
ARGXUSArgenx
35.09x37.17%$60.18B
BIIBUSBiogen
40.07x30.25%$33.45B
ALNYUSAlnylam Pharma
43.11x183.00%$33.40B
HALOUSHalozyme Therap
31.62x181.51%$13.08B
KRYSUSKrystal Biotech
42.29x10.42%$10.21B
VCYTUSVeracyte
34.09x35.02%$3.90B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.